Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
Harvard Business School
UBS
Chubb
Accenture
US Department of Justice
McKesson
Julphar

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUVERIS

« Back to Dashboard

Clinical Trials for Luveris

Trial ID Title Status Sponsor Phase Summary
NCT00328926 Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) Terminated EMD Serono Phase 4 Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
NCT00439829 Synchronization of Follicle Wave Emergence and Ovarian Stimulation Completed Royal University Hospital Foundation Phase 4 The objective of the study is to elucidate the effect of synchronizing initiation of ovarian stimulation treatment with follicular wave emergence in poor responder patients undergoing IVF/ICSI and ET. We hypothesize that initiating treatment on day 1 versus day 4 of the cycle will increase the number of follicles recruited and oocytes retrieved.
NCT00439829 Synchronization of Follicle Wave Emergence and Ovarian Stimulation Completed University of Saskatchewan Phase 4 The objective of the study is to elucidate the effect of synchronizing initiation of ovarian stimulation treatment with follicular wave emergence in poor responder patients undergoing IVF/ICSI and ET. We hypothesize that initiating treatment on day 1 versus day 4 of the cycle will increase the number of follicles recruited and oocytes retrieved.
NCT00553293 Nordic Luveris Study Completed Helse Fonna Phase 4 To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.
NCT00553293 Nordic Luveris Study Completed Herlev Hospital Phase 4 To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Luveris

Condition Name

Condition Name for Luveris
Intervention Trials
Infertility 10
Ovulation Induction 3
Reproductive Techniques, Assisted 1
Hyperprolactinemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Luveris
Intervention Trials
Infertility 14
Hypogonadism 3
Infertility, Female 3
Infertility, Male 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Luveris

Trials by Country

Trials by Country for Luveris
Location Trials
United States 5
Spain 4
Canada 2
Austria 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Luveris
Location Trials
New Jersey 2
Massachusetts 1
California 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Luveris

Clinical Trial Phase

Clinical Trial Phase for Luveris
Clinical Trial Phase Trials
Phase 4 8
Phase 3 5
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Luveris
Clinical Trial Phase Trials
Completed 11
Terminated 6
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Luveris

Sponsor Name

Sponsor Name for Luveris
Sponsor Trials
Merck KGaA 7
EMD Serono 3
Merck, S.L., Spain 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Luveris
Sponsor Trials
Other 23
Industry 15
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Daiichi Sankyo
Farmers Insurance
QuintilesIMS
Boehringer Ingelheim
Mallinckrodt
Chubb
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.